O

Omeros Corp
D

OMER

10.910
USD
3.18
(41.05%)
مغلق
حجم التداول
153,316
الربح لكل سهم
-2
العائد الربحي
-
P/E
-3
حجم السوق
632,231,882
أصول ذات صلة
الأخبار

العنوان: Omeros Corp

القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.